Team:Freiburg/Project/1

Introduction

Our team developed a universal toolkit, termed uniCAS, that enables customizable gene regulation in mammalian cells. Therefore, we engineered the recently understood and highly promising CRISPR/Cas9 system. The regulation is based on the RNA-guided Cas9 protein, which allows specific targeting of DNA sequences. Our toolkit comprises not only a standardized Cas9 protein, but also different effector domains for efficient gene activation or repression. We further engineered a modular RNA plasmid for easy implementation of RNA guide sequences. As an additional feature, we established an innovative screening method for assessing the functionality of our uniCAS fusion proteins. Single genes and even whole genetic networks can be modified using our uniCAS toolkit. We think that our toolbox of standardized parts of the CRISPR/Cas9 system offers broad application in research fields such as tissue engineering, stem cell reprogramming and fundamental research.

Introduction to our project

The enormous amount of gene regulation, signal transduction and metabolic pathways gives us a slight idea about what complexity of life really means. This astonishing complexity is one of the most crucial issues to understand, if we want to understand life itself.

Many approaches have been investigated and given us insights into these biological pathways, resulting in more and more elaborate tools. Solutions for the treatment of systemic diseases like cancer or the fine-tuning of cellular processes remain challenging. There is a need for a powerful tool, which enables powerful regulation of whole genetic networks and yet is simple to use. In the last years there have been several approaches which were able to alter gene expression, but they have the flaw that they are only targeting one gene at a time and do not allow flexible modification of entire genomes.

In the last 8 months, our team has been planning, developing and building up a universal toolkit, which enables the regulation of complex networks. A toolkit that allows the simple and flexible regulation of multiple genes by only one protein.

Figure 1: Our uniCAS toolkit The uniCAS toolkit provides 3 different effectors, 2 methods & 1 effector control! By using our toolkit it is possible to efficiently activate or repress gene expression. We also provide devices for controlling our effectors by light. For multiple targeting different DNA sites can be addressed simultaneously by using our RNAimer plasmid. Try working with uniCAS and receive custom-tailored instructions for your desired gene regulation experiment by using our Manual Tool.

The great potential harbored by the CRISPR/Cas9 system provided a great basis for us to modify it in a way that allows multiple, sequence specific gene regulation in mammalian cells.
The first step to a universal toolkit was to generate a sequence specific DNA-binding protein. This was achieved by mutating the DNA-cleavage site of the Cas9 herewith termed dCas9 protein. With the catalytically inactive engineered mutant of Cas9 we were able to influence the DNA-binding locus and direct the protein to requested DNA targets. To establish a tool that influences the gene expression in mammalian cells, we fused different effectors to the dCas9 protein. For gene regulation we used the trans-activator VP16, the repressor-domain KRAB and the histone methyltransferase G9a. These effectors were able to efficiently change the expression rate of a reporter protein SEAP (secreted alcaline phosphatase) and the endogenous signal protein VEGF (vascular endothelial growth factor).

Figure 2: Engineering of the CRISPR/Cas9 system The nuclease function of Cas9 has been mutated. The dCas9 is still able to bind the guiding RNAs and therewith can be directed towards every requested sequence. By fusing effectors to the dCas9, gene regulation of specitic loci can be engineered.

In order to allow for control of gene regulation in a time- and space-dependent manner, we designed various control elements. We engineered and tested light induction systems and also tried to activate the expression upon chemical stimuli.

As dCas9 is a relatively large protein consisting of 1367 amino acids with a molecular weight of 160 kDa, it influences expression rates and toxicity. We designed several truncated versions of dCas9 with the aim to minimize its size and increase the expression rate while retaining the RNA/DNA binding ability.

Last but not least we established a novel ELISA-based method to assess the binding efficiency of the dCas9 proteins: The uniCAS Binding Assay “uniBAss”. uniBAss was shown to be an innovative tool for the characterization of the binding capacity of our dCas9 fusion proteins and the truncated dCas9 versions. The method offers the possibility for high throughput implementation and technological expansion to DNA-binding proteins other than dCas9 such as TAL effectors (TALEs) and zinc fingers (ZFNs).

Hidden as an uncharacterized E. coli locus for more than 15 years [1], Barrangou et al. identified the CRISPR (Clusterd Regularly Interspaced Short Palindromic Repeats) array as a previously unknown adaptive prokaryotic immune system [2]. Almost half of all prokaryotes make use of this defense mechanism. Invasive DNA or even RNA can be specifically recognized and efficiently cleaved. CRISPR/Cas helps prokaryotes controlling the unselective uptake through natural transformation, phage DNA transduction and horizontal gene transfer by conjugation [3]. This unique feature results from the interplay of non-coding RNAs and CRISPR associated (Cas) proteins that are able to cleave invasive DNA. A wide range of different CRISPR subtypes is known [4], [5]. We used CRISPR type II b of S. pyogenes.

The recognition and degradation of invasive DNA by CRISPR/Cas type II occurs in three steps (see Fig. 2):

1. Acquisition: Invasive DNA is recognized via a protospacer adjacent motif (PAM) – the sequence NGG. This sequence is then integrated into the host CRISPR array and is termed spacer. Spacer sequences transcribe for CRISPR RNAs(crRNAs) which help to sequence specifically cleave invasive DNA. Spacer sequences are located between short palindromic repeats. These palindromic repeats are needed for the functionality of the crRNAs.
2. Expression/Transcription: The Cas9 endonuclease is expressed and CRISPR array is transcribed and processed by RNAse III into crRNAs. crRNAs contain the complementary spacer sequence and the direct repeat sequence. The crRNA functions as a guide for the Cas9 protein to specifically trace invasive DNA sequence. Furthermore trans-activating crRNAs (tracrRNA) are transcribed and bind to the direct repeat part of the crRNA [6]. This second type of RNA is required to build a structure that can be bound by the Cas protein.
3. Interference: Repeatedly invading DNA, of which parts have been integrated into the CRISPR locus, is detected by the RNA-protein-complex. Now the endonuclease Cas9 can dispose of the intruding DNA by enzymatically cleaving it.

In short:
This CRISPR/Cas9 system is based on the interplay of three acting components: tracrRNA, crRNA and Cas9 protein. Studies showed that RNAse III for processing the crRNAs is sufficiently available in host cells [7]. crRNA helps to detect complementary invasive DNA, tracrRNA enables the interaction of crRNA and Cas9. The RNA-Cas9 complex binds appropriate DNA and Cas9 cleaves the DNA sequcence specifically.

Unlike ZFNs, TALEs or Meganucleases, Cas9 proteins perform DNA sequence specific binding by utilizing a unique RNA scaffold composed of crRNA and tracrRNA. With about 30 nucleotides corresponding to the target element and the Cas9's helicase activity, Watson-Crick base pairing can be established between crRNAs and the desired DNA. By their short size, crRNAs are easy to order, insert and express from vector plasmids, containing an RNA-Polymerase III driving U6 promoter, like our RNAimer. So far, the only constraint for recognition between crRNA and target DNA is a protospacer adjacent motif - PAM -, located directly 3‘ of the protospacer sequence and containing a NGG triplett. A second, trans-acting crRNA (tracrRNA) mediates pre-processing of the crRNA and indispensably enhances formation of the Cas-crRNA ribonucleoprotein complex [6].

Our toolkit opens up the possibility to deal with a wide range of yet unadressed scientific questions in the near future, including the field of system biology and complex metabolic engineering approaches. Other advantages cover monetary and logistic aspects, as the only component for modification lies indeed within the crRNA itself. In turn, this can be ordered as two corresponding forward and reverse primers - see Team Freiburg's easy crRNA Design Tool. Financial, logistic and human ressources stay at a minimum using the uniCas toolkit for gene regulation. Accordingly, CRISPR/Cas9 systems have already been established for many model organisms, including Saccharomyces cerevisiae, Caenorhabditis elegans, Arabidopsis thaliana, Drosophila melanogaster, Danio rerio and Mus musculus.

The system can possibly be used for tissue engineering, cancer therapy and stem cell reprogramming. Simultaneous regulation of the expression of different pathway enzymes may enhance industrial purposes - e.g. for the production of certain chemical compounds such as amino acids, biofuels or therapeutic drugs in eukaryotic cells. Therefore, stably transfected cells would be of interest.
Moreover, not only metabolic pathways could be targeted. Developmental Biology studies the embryonic patterning and organ formation. By transient dCas9-KRAB interaction with different stem cell factor expressions, possibilities for better understanding and modeling of organism development arise. Induced pluripotent stem cells, for example, are yet made responsible for causing mutagenesis or immunogenicity [9]. Regenerative medicine still deals with basic understanding of reprogramming most cell types and may therefore gain benefits from efficient simultaneously acting dCas9-regulators.
This tool also is of medical interest, as systemical diseases may be cheaply and efficiently investigated. Complex networks, as for instance can be found in cancer cell differentiation, migration and metabolism may be targeted. Frequently, transcriptional master regulators of house-keeping functions and signaling pathways, such as p53, show tremendous down or up regulation in certain tumors [10].
From a speculative point of view, one could therefore suggest to perform sophisticated dCas9-fusion protein high-throughput transcriptome analysis of cancer-related promoters. Targeting should then first be obtained in cancer cell lines with a multiple crRNA plasmid library. Consequently, promising combinations of crRNAs might then be investigated more precisely and maybe, on a long-term perspective, lead to future therapeutic relevance.

References